Cannabis compound CBD stops coronavirus in test tube, but can it treat Covid?
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
WEDNESDAY, MAY 18, 2022
WEDNESDAY, MAY 18, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Cannabis compound CBD stops coronavirus in test tube, but can it treat Covid?

World+Biz

Reuters
25 January, 2022, 11:00 pm
Last modified: 25 January, 2022, 11:20 pm

Related News

  • 22 Covid cases reported in 24hrs
  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • North Korea Covid outbreak is 'worrying' for new variants -WHO

Cannabis compound CBD stops coronavirus in test tube, but can it treat Covid?

Reuters
25 January, 2022, 11:00 pm
Last modified: 25 January, 2022, 11:20 pm
Photo: Kimzy Nanney/Unsplash
Photo: Kimzy Nanney/Unsplash

Early research suggesting that a popular non-psychoactive compound derived from marijuana might help prevent or treat COVID-19 warrants further investigation in rigorous clinical trials, researchers say.

Several recent laboratory studies of cannabidiol, or CBD, have shown promising results, attracting media attention.

However, many other potential COVID treatments that showed promise in test tubes, from hydroxychloroquine to various drugs used to treat cancer and other diseases, ultimately failed to show benefit for COVID-19 patients once studied in clinical trials.

Marsha Rosner of the University of Chicago led a team that found CBD appeared to help curb SARS-CoV-2 in infected cells in laboratory experiments. "Our findings do not say this will work in patients. Our findings make a strong case for a clinical trial," she said.

Using small doses of highly purified CBD that approximate what patients receive in an oral drug already approved for severe epilepsy, Rosner and colleagues found that CBD did not keep the coronavirus from infecting cells in test tubes.

Rather, it acted soon after the virus entered the cells, blocking it from making copies of itself in part via effects on the inflammatory protein interferon. They found similar effects in infected mice, according to a report in Science Advances.

When they looked at a group of adults with severe epilepsy, the researchers found those who were taking the approved CBD drug had lower rates of COVID-19. But a backward look at a small number of patients does not yield conclusive information. Only randomized clinical trials can do that, Rosner said.

"I know my message is not something people want to hear," she said.

Small doses of tetrahydrocannabinol (THC) - the marijuana ingredient that causes the high - cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabichromene (CBC), and cannabigerol (CBG) did not keep the virus out of cells or prevent it from replicating, her team found.

"Not only did THC not work, but combining it with CBD prevented CBD from working," Rosner said.

NO COVID CURES AT CBD DISPENSARY

A separate team reported recently in the Journal of Natural Products that high doses of CBG and CBDA do prevent the coronavirus from breaking into cells.

Richard van Breemen from Oregon State University told Reuters that the doses his team tested were non-toxic to cells. It is not clear yet that similarly high doses would be safe for humans, his team said.

"You want the lowest possible effective dose," Rosner said, because of potential side effects as the drug is filtered through the liver.

The CBD her team tested was more than 98% pure, while purity in commercial products is far lower. "People should not run out and get CBD from their favorite dispensary," she said.

CBD products have become widely available in many forms and have been touted - often without proof from clinical trials - as treatments for pain and other ailments.

Small CBD trials in humans with COVID-19 are underway.

In one completed study, researchers in Brazil randomly assigned 105 patients with mild or moderate COVID-19 to receive CBD or a placebo for 14 days along with standard care. The CBD had no apparent effect, according to an October report in Cannabis and Cannabinoid Research.

In a proof-of-concept study at Sheba Medical Center in Israel, researchers are randomly assigning patients with mild COVID to receive CBD or a placebo.

An early-stage trial at Rabin Medical Center, also in Israel, aims to test the effect of CBD in severely or critically ill patients. However, study leader Dr. Moshe Yeshurun told Reuters that accruing participants has been difficult because the current Omicron-driven coronavirus wave "consists mostly of patients with mild to moderate disease."

Rosner's team is exploring the possibility of a clinical trial that would likely focus on asymptomatic or mild cases of COVID. Meanwhile, she is concerned that media reports overstating the potential of cannabinoids will lead people to self-medicate with CBD, stop using masks and avoid vaccines.

"We would love to be able to say specifically" that a certain dose of cannabinoids is helpful, she said, but at this point, "vaccine-induced antibodies and antibody drugs are much more effective at blocking infection."

Top News

Cannabis / Covid -19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Sri Lanka default hints at trouble ahead for developing nations
    Sri Lanka default hints at trouble ahead for developing nations
  • BNP has no right to talk on polls as it tainted election process most: PM
    BNP has no right to talk on polls as it tainted election process most: PM
  • Photo: MumitM/TBS
    BERC recommends 57.83% hike in bulk electricity price

MOST VIEWED

  • A sign for BlackRock Inc hangs above the company's building in New York U.S., July 16, 2018. REUTERS/Lucas Jackson
    Global bond ETF industry to triple to $5 trillion by 2030 - BlackRock
  • Photo of World Bank. Photo: Collected
    World Bank to offer $30B over 15 months to ease looming food crisis-Treasury report
  • A woman walks past the embassy of France in Moscow, Russia March 29, 2018. REUTERS/Maxim Shemetov
    Russia expels 85 diplomats from France, Spain and Italy
  • Sri Lanka default hints at trouble ahead for developing nations
    Sri Lanka default hints at trouble ahead for developing nations
  • An army member stops vehicles at a check point on a the main road after the curfew was extended for another extra day following a clash between Anti-government demonstrators and Sri Lanka's ruling party supporters, amid the country's economic crisis, in Colombo, Sri Lanka, May 11, 2022. REUTERS/Dinuka Liyanawatte/File Photo
    Sri Lankan police arrests ruling party MPs over mob violence
  • A woman shops for cooking oil made from oil palms at a supermarket in Jakarta, Indonesia, March 27, 2022. REUTERS/Willy Kurniawan
    Indonesia hopes new programme will help lower cooking oil prices

Related News

  • 22 Covid cases reported in 24hrs
  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • North Korea Covid outbreak is 'worrying' for new variants -WHO

Features

‘The geopolitical landscape is undergoing profound change, Dhaka needs to craft proactive strategies’

‘The geopolitical landscape is undergoing profound change, Dhaka needs to craft proactive strategies’

10h | Interviews
Graphics: TBS

Facebook and Bangladeshi politicians: A new tide in mass political communication?

11h | Panorama
Despite Bangladesh having about 24,000 km of waterways, only a few hundred kilometres are covered by commercial launch services. Photo: Saad Abdullah

Utilising waterways: When common home-goers show the way

1d | Panorama
Illustration: TBS

How Putin revived Nato

1d | Panorama

More Videos from TBS

Bakery business in crisis for increased raw material prices

Bakery business in crisis for increased raw material prices

1h | Videos
Foods that have the most protein

Foods that have the most protein

1h | Videos
How Putin revived Nato

How Putin revived Nato

5h | Videos
Paddle steamers in Bangladesh

Paddle steamers in Bangladesh

10h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

5
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

6
Impact of falling taka against US dollar
Banking

Taka losing more value as global currency market volatility persists

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab